MultiOmic Health
MultiOmic Health is a London-based AI precision medicine company that uses its MOHSAIC® platform combining multi-omics data, systems biology modeling, and wet lab validation to discover patient endotypes and develop targeted therapeutics and companion diagnostics for cardio-renal-metabolic diseases.
- Company typePrivate
- Founded2021
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What MultiOmic Health does
MultiOmic Health is a London-based, privately held precision medicine discovery company founded in 2021 that applies its proprietary MOHSAIC® platform to cardio-renal-metabolic (CRM) diseases, with an initial focus on chronic kidney disease and diabetic kidney disease. The platform integrates deep longitudinal patient datasets, multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics) up to 500 Gb per patient, AI-enabled patient stratification models, computational systems biology simulations using ordinary differential equations, and targeted wet laboratory validation to identify molecularly distinct patient endotypes and generate novel drug targets with companion diagnostics.
The company's product portfolio spans the MOHSAIC platform itself, AI-enabled Renal Endotyping and Patient-Stratifying Models (PSM) designed for SaMD and IVD deployment, Patient-Stratified Renal Drug Targets with Companion Diagnostics, and a Global CRM Patient Registry targeting over 100,000 patients by 2028. The business model is B2B enterprise value-sharing: upfront and milestone payments plus royalties from biopharma co-development and technology licensing agreements, IP out-licensing to medtech for companion diagnostics, and research service fees from collaborative R&D projects. Biopharma companies are the primary customer segment, with NHS and academic institutions serving as data and sample partners.
MultiOmic Health has raised approximately US$13 million across three funding rounds led by Fifty Years, Hoxton Ventures, and Ada Ventures, with participation from MMC Ventures, Verve Ventures, Formic Ventures, HOF Capital, and Selvedge Venture. The company has established a joint venture (RenalDevCo) with Alloy Therapeutics' 82VS studio, research collaborations with Northern Care Alliance NHS Foundation Trust, Queen's University Belfast, and Mesh Bio, and an MoU with BIO4 Campus in Serbia. It operates with a small team of approximately 10 members and no publicly disclosed revenue.
MultiOmic Health firmographics
Firmographics- Name
- MultiOmic Health
- Legal name
- Multiomic Health Limited
- Website
- https://multiomic.health
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MultiOmic Health is a London-based AI precision medicine company that uses its MOHSAIC® platform combining multi-omics data, systems biology modeling, and wet lab validation to discover patient endotypes and develop targeted therapeutics and companion diagnostics for cardio-renal-metabolic diseases.
- Ownership category
- akta.pro rank
MultiOmic Health industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where MultiOmic Health is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
MultiOmic Health business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Value-Sharing Partnerships with Biopharma: Upfront and contingent milestone payments plus sales royalties on marketed drugs. Partnership structures include jointly funded and co-owned drug discovery programs on new targets; technology partnering/licensing arrangements to reposition collaborator's drug assets; and in-licensing 'fallen angel' NMEs for repositioning.
- Intellectual Property Licensing to Medtech: Out-licensing IP to medical technology companies for developing companion diagnostic and clinical biomarker products.
- Collaborative R&D Projects: Joint projects with healthtech companies and pharma to enhance patient stratification for clinical-stage R&D programs, generating research service fees.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
MultiOmic Health product offering
Product offeringCore offering
MultiOmic Health develops the MOHSAIC® platform, an AI-enabled precision medicine discovery engine that integrates multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics) with longitudinal clinical phenotyping, computational systems biology modeling, and wet laboratory validation to identify patient endotypes and discover precision therapeutic concepts. The company focuses on cardio-renal-metabolic diseases, starting with chronic kidney disease, and commercializes its outputs through biopharma partnerships, IP licensing, and collaborative R&D projects.
Product overview
MultiOmic Health operates as an AI-enabled precision medicine discovery company with the MOHSAIC® platform as its core technology foundation. The platform integrates multi-omics analysis with computational systems biology and wet laboratory experiments to identify patient endotypes and develop precision therapeutic concepts for cardio-renal-metabolic diseases. The company builds proprietary datasets through its global CRM patient registry and develops downstream products including renal endotyping models (PSM) and companion diagnostics (CDx) for patient-stratified drug targets. The portfolio spans from data-driven discovery platforms to diagnostic biomarkers, all focused on chronic kidney disease and metabolic syndrome complications.
Differentiator
Problem solved
Functional benefit
Brands
- MOHSAIC: AI-enabled precision medicine discovery platform combining multi-omics data analysis, computational systems biology modeling, and wet laboratory experiments to identify patient endotypes and develop precision therapeutics
Products and services
- MOHSAIC® Platform AI-enabled precision medicine discovery platform combining proprietary patient datasets, multi-omics data integration (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics), AI/ML analytics, computational systems biology modeling, and targeted wet laboratory experiments to identify patient endotypes and discover precision therapeutic concepts for chronic multifactorial diseases. Used by biopharma, medtech, and academic collaborators.
- Renal Endotyping and Patient-Stratifying Models (PSM) AI-enabled diagnostic models that cluster diabetic kidney disease (DKD) patients into clinical phenotypes with distinct molecular signatures, enabling prediction of disease progression trajectories at early disease stage. Designed to be optimized and implemented as SaMD (Software as a Medical Device) and IVD (In Vitro Diagnostic) products for biopharma and medtech partners.
- Patient-Stratified Renal Drug Targets with Companion Diagnostics (CDx) Novel drug targets identified for specific patient endotypes in kidney inflammation and fibrosis, paired with companion diagnostic biomarkers for patient selection in clinical trials. Designed to enable precision medicines with higher efficacy for specific patient subpopulations and to be out-licensed to biopharma partners for clinical development.
Quantifiable outcome
- Patient endotypes identified with distinct molecular signatures enabling precise disease trajectory prediction in diabetic kidney disease.
- +2 more outcomes
Companies that use MultiOmic Health
Customer profileSegments3 records
Ideal customer profiles4 records
MultiOmic Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
MultiOmic Health partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- BIO4 CampusminorMoU signed to explore collaborative opportunities in biomedicine, biotechnology, and bioinformatics with strong emphasis on AI applications. Collaboration supports bioeconomy growth in Serbia.
- Alloy Therapeutics Inc.coreMoU to jointly discover and develop first-in-class renal tissue-targeting drugs. Alloy deploys bispecific antibody and genetic medicine platforms to modulate MOH-identified drug targets. 82VS venture studio establishes 'RenalDevCo' to license IP from both parties. Both receive equity stakes, development milestone payments, and single digit royalties. MOH receives research services payments for IND-enabling studies and clinical trial management.
- Queen's University BelfastcoreTwo-year collaborative project partially funded by Innovate UK's £20M Advancing Precision Medicine programme. MultiOmic deploys MOHSAIC® platform to analyze data from NICOLA and FinnDiane cohorts for diagnostic tools in diabetic kidney disease. Aims to identify biomarkers for DKD progression and complications in specific patient subpopulations.
- Northern Care Alliance NHS Foundation TrustcoreResearch collaboration deploying MOHSAIC® platform on de-identified bio-samples and clinical histories from Salford Kidney Study (one of largest CKD cohorts globally) to investigate patient stratifying biomarkers in diabetic nephropathy using integrative multi-omics analyses.
- Mesh BiocorePartnership to conduct observational clinical study on patients with chronic metabolic disease and increased CKD risk. Mesh recruits patients through healthcare provider network; MultiOmic generates multi-omics data from anonymized samples. Provides access to underrepresented Asian patient populations.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
MultiOmic Health competitors and assessment
Company assessmentDirect peers
- Insitro: Insitro combines machine learning, high-throughput biology, and human genetics to transform drug discovery. Directly comparable to MultiOmic's approach of using multi-omics data and AI to identify patient subpopulations and novel drug targets, particularly in metabolic and neurological diseases.
- Exscientia: Exscientia is an AI-driven precision medicine company using its proprietary platform to design and develop novel drug candidates, with patient-derived data integration. Comparable business model of using AI and patient data to enable biopharma partnerships and precision drug discovery.
- Relation Therapeutics: Relation Therapeutics combines causal ML with multi-omics data to identify novel drug targets. Directly comparable to MultiOmic's approach of integrating multi-omics with AI to discover druggable targets, with similar disease-agnostic platform positioning.
- BenevolentAI: BenevolentAI combines AI, machine learning, and biomedical knowledge graphs to accelerate drug discovery. Comparable to MultiOmic as an AI-driven drug discovery platform that identifies novel targets and partners with pharma for development.
- Recursion Pharmaceuticals: Recursion is an AI-enabled drug discovery platform combining high-throughput biology, automated experimentation, and machine learning to identify novel therapeutic candidates. Highly comparable to MultiOmic as a techbio company building proprietary datasets and AI models to drive drug discovery, though Recursion operates at much larger scale and broader therapeutic scope.
- BioAge Labs: BioAge Labs is an AI-driven biotech focused on metabolic disease drug discovery, using machine learning and patient data to identify targets for age-related conditions. Closely comparable to MultiOmic in therapeutic area (metabolic disease), AI approach, and stage of development.
- Owkin: Owkin is an AI precision medicine company using federated learning and multi-omics analysis to identify biomarkers and develop diagnostics. Highly comparable to MultiOmic's multi-omics + AI approach to patient stratification and biomarker discovery, with similar B2B model selling into biopharma.
Emerging players
- ProKidney: ProKidney is a clinical-stage biotech developing cell therapy for chronic kidney disease. Comparable therapeutic focus on CKD (MultiOmic's first indication) but uses a different modality (cell therapy vs. precision medicine/biologics) and is at later clinical stage.
- Cardior Pharmaceuticals: Cardior Pharmaceuticals develops RNA-based therapeutics for heart failure and associated cardiac diseases, with precision medicine approaches targeting specific patient subgroups. Comparable focus on cardio-renal therapeutic area and patient stratification strategies, though at later stage with clinical assets.
Broad incumbents
- Tempus AI: Tempus is a precision medicine data and technology company combining multi-omics profiling (genomics, transcriptomics, proteomics) with AI to enable pharma R&D and clinical decision support. Comparable to MultiOmic's data integration approach but operating at much larger scale with broader offerings and an established commercial presence.
Market position
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
MultiOmic Health social profiles
Digital presenceMultiOmic Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
MultiOmic Health leadership team
Management profileNumber of profiles
Profiles18 records
MultiOmic Health funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MultiOmic Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MultiOmic Health
What does MultiOmic Health do?
MultiOmic Health develops the MOHSAIC® platform, an AI-enabled precision medicine discovery engine that integrates multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics) with longitudinal clinical phenotyping, computational systems biology modeling, and wet laboratory validation to identify patient endotypes and discover precision therapeutic concepts. The company focuses on cardio-renal-metabolic diseases, starting with chronic kidney disease, and commercializes its outputs through biopharma partnerships, IP licensing, and collaborative R&D projects.
Is MultiOmic Health a public or private company?
MultiOmic Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was MultiOmic Health founded?
MultiOmic Health was founded in 2021. It employs 1 to 10 people.
Where is MultiOmic Health based?
MultiOmic Health is headquartered in London, United Kingdom, in the Europe region.
How does MultiOmic Health make money?
Three revenue lines are on record. Value-Sharing Partnerships with Biopharma is the primary driver. The others are intellectual Property Licensing to Medtech and collaborative R&D Projects.
Who are MultiOmic Health's main competitors?
Direct peers on record are Insitro, Exscientia, Relation Therapeutics, BenevolentAI, Recursion Pharmaceuticals, BioAge Labs and Owkin. Emerging players are ProKidney and Cardior Pharmaceuticals. Tempus AI is listed as a broad incumbent.
Does MultiOmic Health have an API?
No public API is recorded for MultiOmic Health.
What industry is MultiOmic Health in?
MultiOmic Health's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 8731.